EPISODE · Feb 26, 2026 · 9 MIN
#101 $RARE Ultragenyx Stronger Bones or Broken Thesis
from SueWallSt · host SueWallSt
In this episode of Sue Wall Street Holding Wall Street Accountable, we break down the securities class action involving $RARE Ultragenyx and its Phase Three Orbit and Cosmic trials for setrusumab in osteogenesis imperfecta. We examine bone mineral density gains, failed fracture reduction endpoints, interim analysis results, the forty two percent stock drop, and alleged misleading statements about clinical trial confidence. This deep dive is for biotech investors, healthcare traders, and anyone following rare disease drug development, FDA pathways, and securities litigation news. Visit ZLK.com for more info. Add our WhatsApp Channel. We’re not lawyers or accountants, so don’t take this as legal or financial advice.
What this episode covers
In this episode of Sue Wall Street Holding Wall Street Accountable, we break down the securities class action involving $RARE Ultragenyx and its Phase Three Orbit and Cosmic trials for setrusumab in osteogenesis imperfecta. We examine bone mineral density gains, failed fracture reduction endpoints, interim analysis results, the forty two percent stock drop, and alleged misleading statements about clinical trial confidence. This deep dive is for biotech investors, healthcare traders, and anyone following rare disease drug development, FDA pathways, and securities litigation news. Visit ZLK.com for more info. Add our WhatsApp Channel. We’re not lawyers or accountants, so don’t take this as legal or financial advice.
NOW PLAYING
#101 $RARE Ultragenyx Stronger Bones or Broken Thesis
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.